Media stories about TherapeuticsMD (NASDAQ:TXMD) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TherapeuticsMD earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.8883271482097 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- What Does Stochastic %K say about TherapeuticsMD, Inc. (NYSE:TXMD)? – The Oracle Examiner (oracleexaminer.com)
- TherapeuticsMD (TXMD) Reports Nine Presentations Related to TX-004HR and TX-001HR at NAMS – StreetInsider.com (streetinsider.com)
- TherapeuticsMD, Inc. (Nasdaq: TXMD) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its Listing On … – GlobeNewswire (press release) (globenewswire.com)
- TherapeuticsMD Announces Multiple Presentations Related to TX-004HR and TX-001HR at NAMS 2017 (finance.yahoo.com)
- TherapeuticsMD, Inc. :TXMD-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 (finance.yahoo.com)
Shares of TherapeuticsMD (NASDAQ:TXMD) traded down 1.23% on Wednesday, hitting $4.82. 2,035,272 shares of the stock traded hands. The stock has a 50 day moving average price of $5.00 and a 200-day moving average price of $5.00. The stock’s market cap is $983.41 million. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. The company had revenue of $4.25 million for the quarter, compared to analysts’ expectations of $4.91 million. TherapeuticsMD had a negative net margin of 462.94% and a negative return on equity of 77.41%. TherapeuticsMD’s revenue was down 3.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.11) EPS. On average, equities research analysts forecast that TherapeuticsMD will post ($0.44) EPS for the current year.
Several research firms have weighed in on TXMD. Oppenheimer Holdings, Inc. set a $10.00 price target on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Thursday, August 17th. Jefferies Group LLC reissued a “buy” rating and issued a $15.00 price target on shares of TherapeuticsMD in a report on Friday, August 11th. Noble Financial reissued a “buy” rating on shares of TherapeuticsMD in a report on Friday, August 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $33.00 price target on shares of TherapeuticsMD in a report on Tuesday, August 15th. Finally, Zacks Investment Research raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. TherapeuticsMD presently has a consensus rating of “Buy” and a consensus target price of $14.88.
WARNING: This piece of content was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/10/11/therapeuticsmd-txmd-receiving-somewhat-favorable-press-coverage-study-finds.html.
In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were bought at an average cost of $5.99 per share, for a total transaction of $29,950.00. Following the purchase, the director now owns 3,555 shares of the company’s stock, valued at approximately $21,294.45. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
What are top analysts saying about TherapeuticsMD Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TherapeuticsMD Inc and related companies.